Equities research analysts forecast that Cantel Medical Corp. (NYSE:CMD) will report sales of $250.70 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Cantel Medical’s earnings, with the lowest sales estimate coming in at $247.70 million and the highest estimate coming in at $253.70 million. Cantel Medical posted sales of $225.59 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 11.1%. The business is expected to report its next earnings report before the market opens on Tuesday, December 10th.
On average, analysts expect that Cantel Medical will report full year sales of $1.16 billion for the current year. For the next financial year, analysts expect that the company will report sales of $1.28 billion, with estimates ranging from $1.28 billion to $1.29 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Cantel Medical.
Cantel Medical (NYSE:CMD) last issued its earnings results on Monday, September 23rd. The company reported $0.63 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.61 by $0.02. Cantel Medical had a return on equity of 15.34% and a net margin of 5.99%. The business had revenue of $239.48 million during the quarter, compared to analyst estimates of $238.60 million.
Shares of Cantel Medical stock traded down $0.26 during trading hours on Monday, reaching $77.77. 173,489 shares of the stock traded hands, compared to its average volume of 263,572. The company has a 50 day moving average price of $73.19 and a 200 day moving average price of $78.22. The firm has a market capitalization of $3.32 billion, a price-to-earnings ratio of 32.84 and a beta of 1.00. Cantel Medical has a one year low of $63.47 and a one year high of $93.87. The company has a quick ratio of 1.41, a current ratio of 2.32 and a debt-to-equity ratio of 0.33.
Cantel Medical Company Profile
Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company's Endoscopy segment offers automated endoscope reprocessing systems; infectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets, transport systems, and mobile medical carts; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services.
Featured Story: How to Trade Using Analysts Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cantel Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical and related companies with MarketBeat.com's FREE daily email newsletter.